Why the study?
Doxorubicin is an effective antineoplastic drug limited by cardiotoxicity, and the potential protective effects of erythropoietin against doxorubicin-induced cardiomyopathy were investigated.
Does erythropoietin prevent cardiac dysfunction in doxorubicin-induced cardiomyopathy in mice?
Population
Mice with doxorubicin-induced cardiomyopathy
Comparison
Human recombinant erythropoietin started simultaneously with doxorubicin vs doxorubicin alone
Design
Preclinical experimental study with in vitro cardiomyocyte experiments
Follow-up
2 weeks
Authors
Loading...
Hypothesis-generating in mice; leaves open translation to doxorubicin cardiomyopathy prevention in patients.
Does erythropoietin prevent cardiac dysfunction in doxorubicin-induced cardiomyopathy in mice?
Erythropoietin demonstrates cardioprotective effects against doxorubicin-induced cardiomyopathy when administered simultaneously, but is ineffective once cardiac dysfunction is established.
Li et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: